GlassScriptPhysician profile
Musharraf Navaid
NPI 1821061755
$3,394.73
in general payments reported to CMS, 2019-2025
39 companies · $220 in 2025
The $220 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,278 · 2020: $363 · 2021: $58.55 · 2022: $72.75 · 2023: $103 · 2024: $300 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $512.60 |
| Education | $109.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $385.53 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $354.08 | 2019-2025 | |
| Astellas Pharma US INC | $255.34 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $247.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $197.84 | 2019-2024 | Keytruda, Welireg |
| Exelixis INC. | $166.44 | 2019-2025 | Cabometyx |
| Alexion Pharmaceuticals, INC. | $163.21 | 2019-2020 | |
| Lilly USA, LLC | $147.84 | 2019 | |
| Dendreon Pharmaceuticals LLC | $147.11 | 2022-2025 | Provenge |
| Celgene Corporation | $116.00 | 2019-2020 | |
| Genentech USA, INC. | $112.07 | 2019 | |
| Amgen INC. | $110.78 | 2019-2020 | |
| Eisai INC. | $108.98 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $100.45 | 2019 | |
| Emd Serono, INC. | $85.25 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $64.36 | 2019-2020 | |
| Gilead Sciences, INC. | $62.26 | 2022-2024 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $60.27 | 2019-2020 | |
| Genzyme Corporation | $59.02 | 2019 | |
| Jazz Pharmaceuticals INC. | $51.00 | 2019-2020 | |
| Janssen Biotech, INC. | $47.24 | 2019 | |
| Shire North American Group INC | $43.68 | 2019 | |
| Abbvie INC. | $33.33 | 2019-2020 | |
| Seagen INC. | $30.68 | 2019 | |
| Sumitomo Pharma America, INC. | $24.45 | 2024 | Orgovyx |
| Tempus Ai, INC | $23.03 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $21.45 | 2019 | |
| Tesaro, INC. | $19.35 | 2019 | |
| Tersera Therapeutics LLC | $18.89 | 2020 | |
| Glaxosmithkline, LLC. | $15.82 | 2025 | Ojjaara, Jemperli, Zejula |
| Daiichi Sankyo INC. | $15.71 | 2020 | |
| Rigel Pharmaceuticals, INC. | $15.32 | 2019 | |
| Dova Pharmaceuticals | $15.12 | 2019 | |
| Btg International INC. | $14.81 | 2019 | |
| Servier Pharmaceuticals LLC | $14.70 | 2024 | |
| Karyopharm Therapeutics INC. | $13.47 | 2020 | |
| Kyowa Kirin, INC. | $11.14 | 2019 | |
| Incyte Corporation | $11.12 | 2019 | |
| Secura Bio, INC. | $9.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Musharraf Navaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.